Patent ID: 6346249
Filing Date: 2002-02-12
Classification: A61K,C07K

Abstract:
A method of reducing the effects of a cancer that expresses A33 antigen in a subject comprising administering to said subject a pharmaceutically effective amount of an anti-cancer agent conjugated to an immunoglobulin molecule, wherein said immunoglobulin molecule binds with specificity to A33 antigen and comprises six complementarity determining regions (CDRs) the amino acid sequences of which selected from the group consisting of:(i) SEQ ID NO.: 68 or SEQ ID NO.: 69 (VLCDR1); (ii) SEQ ID NO.: 70 or SEQ ID NO.: 71 (VLCDR2); (iii) SEQ ID NO.: 72 or SEQ ID NO.: 73 (VLCDR3); (iv) SEQ ID NO.: 74 or SEQ ID NO.: 75 (VHCDR1); (v) SEQ ID NO.: 76, SEQ ID NO.: 77 or SEQ ID NO.: 78 (VHCDR2); and (vi) SEQ ID NO.: 79 or SEQ ID NO.: 80 (VHCDR3), wherein (i), (ii), (iii), (iv), (v), and (vi) are present in said immunoglobulin molecule sufficient to reduce effect of said cancer that expresses A33 antigen.